J
Jin-Yuan Shih
Researcher at National Taiwan University
Publications - 281
Citations - 15872
Jin-Yuan Shih is an academic researcher from National Taiwan University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 57, co-authored 259 publications receiving 13593 citations. Previous affiliations of Jin-Yuan Shih include University of Texas Southwestern Medical Center & National University of Singapore.
Papers
More filters
Journal ArticleDOI
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Jonathan F. Bean,Cameron Brennan,Jin-Yuan Shih,Gregory J. Riely,Gregory J. Riely,Agnes Viale,Lu Wang,Dhananjay Chitale,Noriko Motoi,Noriko Motoi,Janos Szoke,Stephen Broderick,Marissa Balak,Wen Cheng Chang,Chong-Jen Yu,Adi F. Gazdar,Harvey I. Pass,Valerie W. Rusch,William L. Gerald,Shiu Feng Huang,Pan-Chyr Yang,Vincent Miller,Vincent Miller,Marc Ladanyi,Chih-Hsin Yang,William Pao,William Pao +26 more
TL;DR: Analysis of tumor samples from multiple independent patient cohorts and array-based comparative genomic hybridization suggest that MET amplification occurs independently of EGFRT790M mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib.
Journal ArticleDOI
Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression
Hui-Wen Lo,Sheng-Chieh Hsu,Weiya Xia,Xinyu Cao,Jin-Yuan Shih,Jin-Yuan Shih,Yongkun Wei,James L. Abbruzzese,Gabriel N. Hortobagyi,Mien Chie Hung +9 more
TL;DR: It is shown that EGF induces EGFR-expressing cancer cells to undergo a transition from the epithelial to the spindle-like mesenchymal morphology and induce cancer cell EMT via STAT3-mediated TWIST gene expression.
Journal ArticleDOI
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.
Hui-Wen Lo,Sheng-Chieh Hsu,Mohamed Ali-Seyed,Mehmet Gunduz,Weiya Xia,Yongkun Wei,Geoffrey Bartholomeusz,Jin-Yuan Shih,Mien Chie Hung +8 more
TL;DR: It is reported that EGFR physically interacts with signal transducers and activators of transcription 3 (STAT3) in the nucleus, leading to transcriptional activation of inducible nitric oxide synthase (iNOS) in breast carcinomas.
Journal ArticleDOI
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Kang-Yi Su,Hsuan-Yu Chen,Ker-Chau Li,Ming-Liang Kuo,James Chih-Hsin Yang,Wing-Kai Chan,Bing-Ching Ho,Gee-Chen Chang,Jin-Yuan Shih,Sung-Liang Yu,Pan-Chyr Yang +10 more
TL;DR: T790M may not be a rare event before or after TKI therapy in patients with NSCLC with EGFR-activating mutations, and was an independent predictor of decreased progression-free survival (PFS) in patients who received TKI treatment.
Journal ArticleDOI
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu,Jin-Yuan Shih +1 more
TL;DR: Understanding and clarifying the biology of the resistance mechanisms of EGFR-mutant NSCLC could guide future drug development, leading to more precise therapy and advances in treatment.